Autologous Ebv-Ctl Transduced With Vector Sfg-Cna12
Transplant-Related Hematologic Malignancy
University College, LondonCell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Transplant-Related Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Treosulfan IRCCS San Raffaele | Phase 2 | BB |
Fludarabine IRCCS San Raffaele | Phase 2 | B |
Cytosin-Arabinosid Ciceri Fabio | Phase 2 | B |
Thiotepa Ciceri Fabio | Phase 2 | B |
Revumenib Center for International Blood and Marrow Transplant Research | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Autologous Ebv-Ctl Transduced With Vector Sfg-Cna12 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →